Jennifer Kayden Lee Sells 1,447 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) EVP Jennifer Kayden Lee sold 1,447 shares of the business's stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $59.43, for a total value of $85,995.21. Following the sale, the executive vice president now owns 4,038 shares in the company, valued at approximately $239,978.34. The trade was a 26.38 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Jennifer Kayden Lee also recently made the following trade(s):

• On Monday, November 11th, Jennifer Kayden Lee sold 66,861 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $66.33, for a total value of $4,434,890.13.

Rhythm Pharmaceuticals Trading Down 1.4 %

RYTM stock traded down $0.83 during midday trading on Friday, reaching $59.18. The company had a trading volume of 372,997 shares, compared to its average volume of 477,675. The company has a 50 day moving average of $57.26 and a two-hundred day moving average of $53.30. The company has a market capitalization of $3.64 billion, a P/E ratio of -13.67 and a beta of 2.14. Rhythm Pharmaceuticals, Inc. has a 1 year low of $35.17 and a 1 year high of $68.58.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last issued its earnings results on Tuesday, November 5th. The company reported ($0.73) EPS for the quarter, beating analysts' consensus estimates of ($0.80) by $0.07. The firm had revenue of $33.20 million for the quarter, compared to the consensus estimate of $32.52 million. Rhythm Pharmaceuticals had a negative return on equity of 367.36% and a negative net margin of 230.07%. The business's quarterly revenue was up 47.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.76) earnings per share. On average, sell-side analysts anticipate that Rhythm Pharmaceuticals, Inc. will post -4.33 earnings per share for the current year.

Institutional Trading of Rhythm Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. Castleark Management LLC boosted its stake in shares of Rhythm Pharmaceuticals by 1.3% during the 3rd quarter. Castleark Management LLC now owns 19,260 shares of the company's stock worth $1,009,000 after acquiring an additional 250 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Rhythm Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,211 shares of the company's stock valued at $114,000 after buying an additional 391 shares during the last quarter. SRS Capital Advisors Inc. raised its holdings in Rhythm Pharmaceuticals by 740.7% in the 4th quarter. SRS Capital Advisors Inc. now owns 454 shares of the company's stock worth $25,000 after acquiring an additional 400 shares during the period. Raleigh Capital Management Inc. acquired a new position in Rhythm Pharmaceuticals during the 4th quarter worth $28,000. Finally, SBI Securities Co. Ltd. acquired a new position in shares of Rhythm Pharmaceuticals during the 4th quarter worth about $37,000.

Analysts Set New Price Targets

RYTM has been the subject of a number of recent analyst reports. HC Wainwright restated a "buy" rating and issued a $69.00 target price on shares of Rhythm Pharmaceuticals in a report on Monday, December 23rd. Needham & Company LLC upped their price target on shares of Rhythm Pharmaceuticals from $55.00 to $64.00 and gave the stock a "buy" rating in a research report on Wednesday, November 6th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $80.00 target price on shares of Rhythm Pharmaceuticals in a research note on Tuesday, November 19th. Oppenheimer assumed coverage on Rhythm Pharmaceuticals in a research report on Friday, December 20th. They issued an "outperform" rating and a $76.00 target price for the company. Finally, Bank of America raised their target price on shares of Rhythm Pharmaceuticals from $48.00 to $52.00 and gave the stock a "neutral" rating in a report on Monday, October 14th. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, Rhythm Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $68.09.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.